Last reviewed · How we verify
midazolam and esketamine
Midazolam and esketamine, marketed by the Second Affiliated Hospital of Wenzhou Medical University, holds a niche position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments in its class. The primary risk is the lack of clear revenue data and key trial results, which may limit its market appeal and investor confidence.
At a glance
| Generic name | midazolam and esketamine |
|---|---|
| Also known as | combination with intranasal esketamine and oral midazolam |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (PHASE3)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation (PHASE1, PHASE2)
- Subanesthetic Esketamine for Hemodynamic Stability and Recovery in Elderly Thoracic Surgery Patients (NA)
- Ketamine in OCD: Efficacy and Effects on Stress and Cognition (NA)
- Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide (PHASE2)
- Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: